Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have received an average rating of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $19.60.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a report on Wednesday, October 8th.

Protara Therapeutics Trading Down 3.4%

NASDAQ TARA opened at $4.29 on Friday. Protara Therapeutics has a 1-year low of $2.21 and a 1-year high of $10.48. The company has a market capitalization of $165.52 million, a price-to-earnings ratio of -2.65 and a beta of 1.59. The stock’s 50 day moving average is $4.33 and its two-hundred day moving average is $3.60.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Monday, August 11th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08. On average, analysts predict that Protara Therapeutics will post -3.32 earnings per share for the current year.

Institutional Trading of Protara Therapeutics

Several hedge funds have recently modified their holdings of TARA. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Protara Therapeutics in the 2nd quarter worth approximately $30,000. Quadrature Capital Ltd bought a new position in Protara Therapeutics in the 2nd quarter valued at $35,000. JPMorgan Chase & Co. bought a new position in Protara Therapeutics in the 2nd quarter valued at $46,000. Los Angeles Capital Management LLC acquired a new position in Protara Therapeutics in the second quarter worth $47,000. Finally, Intech Investment Management LLC bought a new stake in shares of Protara Therapeutics during the second quarter worth $49,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.